Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.
Assessing The Rationale Behind Triplet Regimens in RRMM
June 14th 2024During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Grajales-Cruz Interprets Data for Earlier- Line CAR T-Cell Therapy in R/R MM
June 8th 2024During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Read More
Khouri Analyzes How Daratumumab-Based Quadruplet Therapy Achieves MRD States in Multiple Myeloma
June 7th 2024During a Case-Based Roundtable® event, Jack Khouri, MD, discussed data from the GRIFFIN, PERSEUS, and MASTER trials that investigated quadruplet therapy in patients with newly diagnosed multiple myeloma.
Read More